• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of Hematology >Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial
【24h】

Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial

机译：抗CD20抗体利妥昔单抗维持治疗期间B细胞非霍奇金淋巴瘤患者的生活质量：一项前瞻性随机对照试验的结果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The introduction of rituximab into the primary treatment of malignant lymphomas of the B cell lineage has had a major impact on the management of these diseases. In addition, prolonged exposure to rituximab as maintenance therapy has been beneficial in patients with follicular lymphoma and mantle cell lymphoma. For the individual patient, the effect of any prolonged antitumor therapy on the quality of life (QoL) is a very important question. However, so far, the question whether rituximab maintenance therapy may impair QoL in patients with non-Hodgkin’s lymphoma remains unanswered. To investigate this subject, we have performed a prospective randomized trial of rituximab maintenance therapy (8 cycles rituximab 375 mg/m2 every 3 months) versus observation in patients with CD20+B cell non-Hodgkin’s lymphoma in our institution. Between July 2002 and December 2005, 122 patients were included into the trial. QoL was assessed with the standardized questionnaires EORTC-QLQ-C30, EuroQol-5D, and EuroQol-5D (VAS) in 91 patients. After statistical analysis with the exact Wilcoxon rank sum test, we found no significant differences of the QoL between the rituximab treatment group and the observation group. We conclude that rituximab maintenance therapy seems to be safe and does not impair quality of life in this patient population.
机译：将利妥昔单抗引入B细胞谱系恶性淋巴瘤的一级治疗对这些疾病的治疗产生了重大影响。此外，长期接触利妥昔单抗作为维持治疗对滤泡性淋巴瘤和套细胞淋巴瘤患者有益。对于个体患者，任何延长抗肿瘤治疗对生活质量（QoL）的影响都是一个非常重要的问题。但是，到目前为止，利妥昔单抗维持治疗是否会损害非霍奇金淋巴瘤患者的QoL的问题仍未得到解答。为了研究该受试者，我们进行了一项利妥昔单抗维持治疗的前瞻性随机试验（每3个月进行8个周期的利妥昔单抗375 mg / m 2 ），并比较了CD20 + B细胞非霍奇金淋巴瘤患者的观察结果。我们的机构。在2002年7月至2005年12月之间，该试验纳入了122名患者。使用标准化问卷EORTC-QLQ-C30，EuroQol-5D和EuroQol-5D（VAS）对91名患者进行了QoL评估。通过精确的Wilcoxon秩和检验进行统计分析后，我们发现利妥昔单抗治疗组和观察组之间的QoL没有显着差异。我们得出结论，利妥昔单抗维持治疗似乎是安全的，并且不会损害该患者人群的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号